National Research (NRCIA) Getting Somewhat Favorable Media Coverage, Study Shows

News headlines about National Research (NASDAQ:NRCIA) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. National Research earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the business services provider an impact score of 44.8958119981362 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

NRCIA stock opened at $32.55 on Thursday. National Research has a fifty-two week low of $20.19 and a fifty-two week high of $41.99. The company has a market cap of $783.09, a P/E ratio of 56.12 and a beta of 1.68.

National Research (NASDAQ:NRCIA) last posted its quarterly earnings results on Tuesday, February 13th. The business services provider reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.12). National Research had a return on equity of 27.45% and a net margin of 19.52%. The firm had revenue of $29.90 million for the quarter, compared to analyst estimates of $30.60 million. analysts anticipate that National Research will post 1.11 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 30th will be paid a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date is Wednesday, March 28th. National Research’s dividend payout ratio (DPR) is currently 68.97%.

NRCIA has been the topic of a number of research reports. Zacks Investment Research raised National Research from a “sell” rating to a “hold” rating in a research note on Tuesday, February 6th. BidaskClub downgraded National Research from a “buy” rating to a “hold” rating in a research note on Thursday, February 22nd. Finally, ValuEngine raised National Research from a “hold” rating to a “buy” rating in a research note on Tuesday, April 3rd.

In related news, Director John N. Nunnelly sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $28.75, for a total transaction of $86,250.00. Following the transaction, the director now directly owns 33,261 shares of the company’s stock, valued at approximately $956,253.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Amandla Mk Trust acquired 5,494,440 shares of the stock in a transaction dated Thursday, February 15th. The stock was bought at an average cost of $19.31 per share, with a total value of $106,097,636.40. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 6,870,104 shares of company stock worth $164,329,548. 5.70% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This article was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at

About National Research

National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.

Insider Buying and Selling by Quarter for National Research (NASDAQ:NRCIA)

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with's FREE daily email newsletter.

Leave a Reply